Page 13 - Sun Pharma

Sun Pharma hits 5-month low; stock slips 7%

The stock dipped 7% to Rs 475, its lowest level since June 6, 2018 on the BSE.

Sun Pharma to acquire Japan's Pola Pharma for $1 million for derma products

Sun Pharma Monday said it will acquire Japan-based Pola Pharma for around USD 1 million to strengthen its presence in dermatology segment across the globe. The company has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan, Sun Pharmaceutical Industries said in a statement. Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables. It also has R&D capabilities to develop new technologies and formulations. "This acquisition is in line with our strategy to strengthen our global dermatology presence. Pola Pharma is a leading dermatology company and it will help us launch our speciality and generic dermatology products in the Japanese market in future," Sun Pharma Executive Vice-President Kirti Ganorkar said. Sun Pharma Japan Country Head .

Sun Pharma, subsidiary enter settlements in Modafinil antitrust litigation

The company, however, did not disclose the details of the settlement, saying the terms are confidential

Growth concerns resurface for Sun Pharma after disappointing second quarter

Analysts cut earnings estimates on muted India business growth outlook, rising expenses on specialty launches in the US

Sun Pharma hits three-month low post Q2 results; drops 10% in three days

The stock was down 5 per cent at Rs 533, trading at its lowest level since July 17, 2018, on BSE.

One-time litigation loss, slow domestic business drag Sun Pharma Q2

Company misses revenue estimates too, delivering a top line of Rs 69.37 bn, up a moderate 4.3%. Analysts had expected double-digit revenue growth for the quarter

Sun Pharma's Q2 show marred by one-offs; US growth to drive earnings

Domestic growth is likely to remain firm going ahead, while US growth led by new launches and speciality products should drive earnings

India biz may stabilise in FY19, but govt price caps a concern: Sun Pharma

The company's India business revenues stood at Rs 80.29 billion in 2017-18, a growth of 4 per cent over 2016-17

Sun Pharma looks to grow complex generics, specialty products biz faster

This strategy will entail taking multiple initiatives, both organic and inorganic as well as assuming measured risks

Sun Pharma gets Australian health regulator's nod for plaque psoriasis drug

ILUMYA is one of the key specialty products of Sun Pharma and it was approved by the US health regulator USFDA in March 2018 while the European Commission approved it in September 2018

First USFDA approval for Sun Pharma's Halol plant after warnings

This speciality drug, Sun claimed, is the first and only form of latanoprost that is not formulated with benzalkonium chloride

Sun Pharma shares gain 4% after declining 7% in past three days

The stock has moved higher by 4% to Rs 655, bouncing back 6% from its early morning low of Rs 620 on the BSE on Wednesday.

Sun Pharma's Halol plant is in trouble yet again, gets USFDA observations

Halol, a key plant for the drug maker to manufacture injectables and specialty drugs, was under regulatory scanner since 2014

Sun Pharma gets 6 observations by US FDA after inspection at Halol facility

Shares of Sun Pharmaceutical Industries on Friday closed at Rs 664.20 per scrip on BSE, down 1.84 per cent from its close

Sun Pharma erases losses post clarification on USFDA observations

The stock hit an intra-day high of Rs 670, recovering 4.7% from its early morning low of Rs 640 on the NSE.

Sun Pharma falls 5% on reports of USFDA issues observations

In past three months, Sun Pharma had outperformed the market by surging 38% as compared to a 9% rise in the benchmark index till Thursday.

Sun Pharma, Glenmark Pharma, Hikal hit 52-week highs; Aurobindo surges 8%

Granules India, Hikal, Pfizer, Lincoln Pharmaceuticals, Astrazeneca Pharma India and Aarti Drugs were up between 4% and 7%.

Improved US prospects, domestic outlook to drive Sun Pharma's earnings

The key near-term trigger is the company's specialty pipeline

Pharma shares extend rally; Dr Reddy's, Sun Pharma hit 52-week high

In past 14 trading days, Nifty Pharma index outperformed the market by surging 15% as compared to 2.3% rise in Nifty 50 index.

Nifty Pharma index set to post sharpest monthly rally in 9 years

Nifty Pharma index hit a fresh 52-week high of 10,390 in intra-day on Friday, rallying 13% thus far in the month of August, its sharpest monthly gain since September 2009.